Idiopathic Thrombocytopenic Purpura Therapeutics Market
Idiopathic Thrombocytopenic Purpura Therapeutics Market Analysis by Product Type (Corticosteroids, Intravenous Immunoglobulins, Anti-D Immunoglobulin, Thrombopoietin Receptor Agonists), by Treatment Type (Oral, Splenectomy-based), by Distribution Channel & Regional Forecast 2022 to 2032
Analysis of Idiopathic Thrombocytopenic Purpura Therapeutics market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook (2022 to 2032)
The global idiopathic thrombocytopenic purpura therapeutics market was valued at US$ 587.0 Million in 2021, and is projected to be valued at US$ 620.5 Million in 2022. During the 2022 to 2032 period of assessment, demand is expected to rise at a 5.0% value CAGR, likely to reach US$ 1.0 Billion by the end of the said forecast period.
Overall, the idiopathic thrombocytopenic purpura therapeutics landscape is poised to yield an absolute dollar opportunity worth US$ 390.9 Million until 2032. Sales of Idiopathic Thrombocytopenic Purpura Therapeutics will continue to flourish, with a documented CAGR of 5.6% from 2015 to 2021.
| Report Attributes | Details |
|---|---|
| Anticipated Base Year Value (2021) | US$ 587.0 Million |
| Expected Market Value (2022) | US$ 620.5 Million |
| Projected Forecast Value (2032) | US$ 1.0 Billion |
| Global Growth Rate (2022 to 2032) | 5.0% CAGR |
| Growth Rate of the U.S (2022 to 2032) | 4.8% CAGR |
| Expected Market Value of China (2032) | US$ 72.7 Million |
| Dollar Opportunity in Japan (2022 to 2032) | US$ 16.8 Million |
| Key Idiopathic Thrombocytopenic Purpura Therapeutics Service Providers | Hoffmann-La Roche; Novartis AG; GlaxoSmithKline; Eisai; Grifols Biologicals Inc.; Baxter; Bristol-Myers Squibb; CSL Behring; Sandoz S.A; Contract Pharmaceutical |
Moreover, corticosteroids, by product type, and retail pharmacies, in terms of distribution channel, will continue to remain the primary beneficiaries of the idiopathic thrombocytopenic purpura therapeutics market, likely to register CAGRs worth 5.0% and 5.1% respectively, from 2022 to 2032. The U.S will likely represent the highest share for the idiopathic thrombocytopenic purpura therapeutics market.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Idiopathic Thrombocytopenic Purpura Therapeutics Market Revenue Key Trends
The potential commercialization of new products such as Avatrombopag by Eisai and IVIG3I 10% by Grifols, is one of the major key trends that is expected to fuel the growth of the Idiopathic Thrombocytopenic Purpura Therapeutics market during the forecast period. Avatrombopag has demonstrated positive clinical trial results and is expected to present patients with an alternative second line of treatment upon commercialization.
Increasing demand for combination therapies therapy is expected to fuel the growth of the Idiopathic Thrombocytopenic Purpura Therapeutics market. Clinical evidence suggests that combination therapies entail relatively lower side effects, are cost-effective, and display higher response rates in patients. Some major combination therapies include corticosteroids and IVIG, rituximab and dexamethasone, TPO-RA (eltrombopag), and dexamethasone.
Splenectomy also plays an integral role in shaping the dynamics of the ITP therapeutics market. The procedure refers to the removal of the spleen and is aimed at reducing the amount of anti-platelet antibodies. Two therapeutic classes most affected by splenectomy are TPO-RA and anti-D.
Increasing Monetary Support from Government Organizations and Private Firms
The tertiary and secondary lines of treatment are costly and enforce considerable financial burden to the affected patient suffering from immune thrombocytopenia and associated family members. The government organizations and private firms are proactively collaborating to surge patient access and regulate the drug prices for the management of idiopathic thrombocytopenic purpura. This rising financial support from government and private companies are likely to fuel the immune thrombocytopenia market growth.
In European countries like Germany and France, healthcare reimbursement policies are patient-focused. Around 80% of European countries offer unpaid public health care systems. Combined with this, support organizations like ITP Support Association enable patient alleviate the monetary burden via donations and financial support.
Rising Prevalence of ITP Globally, and Increasing Awareness of the Disorder in the Developed Countries
Rising prevalence of immune thrombocytopenia purpura across different regions of the globe is anticipated to fuel the demand for treatment of the disorder. Increasing incidences of acute as well as prolonged chronic immune thrombocytopenia are projected to drive the acceptance of therapeutics treatment globally during the forecast period.
Increasing awareness about healthcare and rare diseases among patient population and healthcare professionals in emerging countries is anticipated to positively boost the immune thrombocytopenia market growth during the analysis period.
Non-government organizations like Platelet Disorder Support Association and Immune Thrombocytopenia Support Associations are robustly participating in informing the population concerning rare blood disorders like ITP. These initiatives by non-government organizations are projected to augment the therapeutic demand of immune thrombocytopenia drugs market.
Key Challenges Prevalent in the Global Idiopathic Thrombocytopenic Purpura Therapeutics Market
Side Effects of Corticosteroids and Lack of Diagnostic Facilities
The major restraint for the idiopathic thrombocytopenic purpura therapeutics market includes the side effects of corticosteroids or drugs used. Moreover, lack of diagnostic facilities (no facilities for diagnostic test in rural areas), in developing countries is also impeding the growth of the Idiopathic Thrombocytopenic Purpura Therapeutics market during the forecast period.
Lack of Awareness and High Cost of Treatment
Another restraint for idiopathic thrombocytopenic purpura therapeutics market is lack of awareness of disease amongst people, and high cost of treatment in low-income countries. In addition, non-adherence of patients to combination treatment has also been a major part in restraining for idiopathic thrombocytopenic purpura therapeutics market over the analysis period.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Comparative View of Adjacent Idiopathic Thrombocytopenic Purpura Therapeutics Market
Idiopathic Thrombocytop-nic Purpura Therapeutics Market :
| Attributes | Idiopathic Thrombocytop-nic Purpura Therapeutics Market |
|---|---|
| CAGR (2022 to 2032) | 5.0% |
| Market Value (2032) | US$ 1.0 Billion |
| Growth Factor | Rising prevalence of immune thrombocytopenia purpura across different regions of the globe is anticipated to fuel the demand for treatment of the disorder. |
| Opportunity | The government organizations and private firms are proactively collaborating to surge patient access and regulate the drug prices for the management of idiopathic thrombocytopenic purpura, which in turn is anticipated to fuel the market growth. |
| Key Trends | The potential commercialization of new products such as Avatrombopag by Eisai and IVIG3I 10% by Grifols, is one of the major key trends that is expected to fuel the market growth. |
Corticosteroids Market :
| Attributes | Corticosteroids Market |
|---|---|
| CAGR (2022 to 2032) | 4.3% |
| Market Value (2032) | US$ 2.7 Billion |
| Growth Factor | The increasing incidence of chronic diseases is one of the major factors expected to boost the market growth. |
| Opportunity | The surging investment in research and development is expected to fuel the market growth. |
| Key Trends | The uninterrupted incidence and prevalence of chronic diseases lead to the growth of the Corticosteroids market during the forecast period. |
Intravenous Immunoglobulin Market :
| Attributes | Intravenous Immunoglobulin Market |
|---|---|
| CAGR (2022 to 2032) | 7.5% |
| Market Value (2032) | US$ 22.5 Billion |
| Growth Factor | A significant rise in geriatric population & number of hemophilic patients is expected to accelerate the market growth. |
| Opportunity | Improved technologies pertaining to the immunoglobulin production are expected to propel the market growth. |
| Key Trends | A surge in prevalence diseases such as chronic inflammatory demyelinating polyneuropathy (CIDP), hypogammaglobulinemia, and others is expected to boost the market growth. |
Country-wise Analysis
What is the Growth Outlook for Idiopathic Thrombocytopenic Purpura Therapeutics in the U.S?
The demand for Idiopathic Thrombocytopenic Purpura Therapeutics market in the U.S is likely to expand at a 4.8% value CAGR until 2032, forecast to yield an opportunity worth US$ 368.8 Million.
Factors such as higher access to treatment of ITP, larger presence of key market players, advanced healthcare infrastructure, rising awareness of rare blood disorders are expected to positively influence immune thrombocytopenia market in the US.
In addition, increasing infrastructure facilities and higher investments in the development of novel therapeutic molecules for management of ITP in the US are also prominently anticipated to boost the adoption of immune thrombocytopenia treatment in the country during the forecast period.
How do Growth Prospects Appear in the Chinese Market?
China is projected to witness considerable growth in the market due to increasing financial and monetary support from non-government and government organizations towards ITP patients.
Rapidly evolving healthcare infrastructure in China is projected to offer massive potential for increased adoption of the immune thrombocytopenia treatment during the forecast period. China is expected to reach US$ 72.7 Million by 2032, growing at a 4.4% CAGR.
Is Japan likely to emerge as an Opportunistic Idiopathic Thrombocytopenic Purpura Therapeutics Industry?
Japan is also expected to witness a significant growth in terms of market value. Rising awareness about idiopathic thrombocytopenic purpura in the country is expected to propel the demand for thrombopoietin receptor agonist-based treatment during the forecast period. Patients in China are expected to adopt intravenous drugs like TPO-RA and immunoglobulins to improve the disorder.
Additionally, the prospective launch of TAVALISSE in the Japanese market by 2022 could prove to be a driving factor for others treatment segment. Japan is expected to grow at a CAGR of 3.4% and is expected to represent a market share of US$ 58.7 Million by 2032.
Country-wise Forecast CAGRs in the Idiopathic Thrombocytopenic Purpura Therapeutics Market
| Country | CAGR |
|---|---|
| US | 4.8% |
| China | 4.4% |
| Japan | 3.4% |
| UK | 3.7% |
| South Korea | 3.0% |
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Category-wise Insights
By Product Type, which Category’s Demand will Rise Rapidly?
Corticosteroids to be Top Offering in the Coming Years
By product type, corticosteroids are likely to remain the top category, growing at a value CAGR of 5.0% from 2022 to 2032. Corticosteroids, is expected to hold a significant share of the market in the developing countries of Asia Pacific and Latin America, owing to higher adoption and cost-effectiveness of the drug class.
In addition, due to the increasing patient population suffering from immune thrombocytopenia, there is higher demand for different types of treatment. Additionally, technological advancement in diagnostic procedures is increasing the detection rate of this rare blood disorder.
Which Distribution Channel Type is Expected to Leverage Idiopathic Thrombocytopenic Purpura Therapeutics the Most?
Retail Pharmacies to leverage the Market Growth
The Retail Pharmacies channel of the Idiopathic Thrombocytopenic Purpura Therapeutics Market is expected to grow at a value CAGR of 5.1% from 2022 to 2032.
The retail pharmacy segment is projected to have a dominant share because of higher adoption of intravenous treatment of ITP like immunoglobulins and TPO-RA. Moreover, higher incidences of bleeding disorders in individuals suffering from immune thrombocytopenia leads to increase in the adoption of rescue therapy in retail pharmacies. This factor is also facilities retail pharmacy to lead the ITP market.
Moreover, the retail pharmacy segment is growing, owing to increasing number of trends towards oral therapeutic solutions and procurement of the same through retail channels.
Competitive Landscape
The global market for Idiopathic Thrombocytopenic Purpura Therapeutics is characterized by the presence of multiple vendors, aiming to offer extensive products to consumers. Additionally, key makers are focusing on developing the devices supported by the implementation of stringent government regulations, and are offering solutions tailor-made to suit their business objectives. In addition, the vendors are likely to leverage upgradation and product differentiation to gain an edge over other competitors in the market.
- In February 2019, Paras Biopharmaceuticals Finland Oy announced the successful development of biologically active Romiplostim.
- In April 2018, U.S Food and Drug Administration (FDA) approved the therapeutic use of TAVALISSE developed by Rigel Pharmaceuticals, Inc. as the second line of treatment for ITP.
- In March 2018, Dova Pharmaceuticals, along with its wholly-owned subsidiary AkaRx, Inc. entered into a distribution and development rights agreement with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. For DOPTELET in China and Hong Kong.
Key Segments Covered in the Idiopathic Thrombocytopenic Purpura Therapeutics Industry Report
-
By Product Type :
- Corticosteroids-based Idiopathic Thrombocytopenic Purpura Therapeutics
- Intravenous Immunoglobulins-based Idiopathic Thrombocytopenic Purpura Therapeutics
- Anti-D Immunoglobulin-based Idiopathic Thrombocytopenic Purpura Therapeutics
- Thrombopoietin Receptor Agonists (TPO-RA) based Idiopathic Thrombocytopenic Purpura
- Other Idiopathic Thrombocytopenic Purpura Therapeutic Products
-
By Distribution Channel :
- Idiopathic Thrombocytopenic Purpura Therapeutic Product Sales via Drug Stores
- Idiopathic Thrombocytopenic Purpura Therapeutic Product Sales via Retail Pharmacies
- Idiopathic Thrombocytopenic Purpura Therapeutic Product Sales via Other Distribution Channels
-
By Treatment Type :
- Oral Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics
- Prednisone
- Rituximab
- Azathioprine
- Eltrombopag
- Splenectomy-based Idiopathic Thrombocytopenic Purpura Therapeutics
- Intravenous Immunoglobulin (IVIG)
- Anti-D Immunoglobulin
- Thrombopoietin Receptor Agonists
- Oral Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics
-
By Region :
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Table of Content
- 1. Executive Summary
- 2. Market Overview
- 3. Market Risks and Trends Assessment
- 4. Market Background
- 5. Key Success Factors
- 6. Global Market Demand Analysis 2015 to 2021 and Forecast, 2022 to 2032
- 7. Global Market Value Analysis 2015 to 2021 and Forecast, 2022 to 2032
- 8. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Product Type
- 8.1. Corticosteroids
- 8.2. Intravenous immunoglobulins
- 8.3. Anti-D immunoglobulin
- 8.4. Thrombopoietin receptor agonists (TPO-RA)
- 8.5. Others
- 9. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Distribution Channels Type
- 9.1. Drug store
- 9.2. Retail pharmacies
- 9.3. Others
- 10. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Treatment Type
- 10.1. Oral corticosteroids
- 10.1.1. Prednisone
- 10.1.2. Rituximab
- 10.1.3. Azathioprine
- 10.1.4. Eltrombopag
- 10.2. Spleenectomy
- 10.2.1. Intravenous immunoglobulin (IVIG)
- 10.2.2. Anti-D immunoglobulin
- 10.2.3. Thrombopoietin receptor agonists
- 10.1. Oral corticosteroids
- 11. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Region
- 11.1. North America
- 11.2. Latin America
- 11.3. Europe
- 11.4. Asia Pacific
- 11.5. Middle East and Africa (MEA)
- 12. North America Market Analysis 2015 to 2021 and Forecast 2022 to 2032
- 13. Latin America Market Analysis 2015 to 2021 and Forecast 2022 to 2032
- 14. Europe Market Analysis 2015 to 2021 and Forecast 2022 to 2032
- 15. Asia Pacific Market Analysis 2015 to 2021 and Forecast 2022 to 2032
- 16. Middle East and Africa Market Analysis 2015 to 2021 and Forecast 2022 to 2032
- 17. Key Countries Market Analysis 2015 to 2021 and Forecast 2022 to 2032
- 18. Market Structure Analysis
- 19. Competition Analysis
- 19.1. Hoffmann-LA Roche
- 19.2. Novartis
- 19.3. GlaxoSmithKline
- 19.4. Eisai
- 19.5. Amgen
- 19.6. Grifols Biologicals Inc.
- 19.7. Baxter
- 19.8. CSL Behring
- 19.9. Bristol-Myers Squibb
- 19.10. SANDOZ
- 19.11. CONTRACT PHARMACAL
- 20. Assumptions and Acronyms Used
- 21. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Value (US$ Mn), By Product Type, 2015 to 2021
Table 02: Global Market Value (US$ Mn), By Product Type, 2022 to 2032
Table 03: Global Market Value (US$ Mn), By Treatment Type, 2015 to 2021
Table 04: Global Market Value (US$ Mn), By Treatment Type, 2022 to 2032
Table 05: Global Market Value (US$ Mn), By Distribution channels Type, 2015 to 2021
Table 06: Global Market Value (US$ Mn), By Distribution channels Type, 2022 to 2032
Table 07: Global Market, By Region, 2015 to 2021
Table 08: Global Market, By Region, 2022 to 2032
Table 09: North America Market Value (US$ Mn), By Product Type, 2015 to 2021
Table 10: North America Market Value (US$ Mn), By Product Type, 2022 to 2032
Table 11: North America Market Value (US$ Mn), By Treatment Type, 2015 to 2021
Table 12: North America Market Value (US$ Mn), By Treatment Type, 2022 to 2032
Table 13: North America Market Value (US$ Mn), By Distribution channels Type, 2015 to 2021
Table 14: North America Market Value (US$ Mn), By Distribution channels Type, 2022 to 2032
Table 15: North America Market, By Country, 2015 to 2021
Table 16: North America Market, By Country, 2022 to 2032
Table 17: Latin America Market Value (US$ Mn), By Product Type, 2015 to 2021
Table 18: Latin America Market Value (US$ Mn), By Product Type, 2022 to 2032
Table 19: Latin America Market Value (US$ Mn), By Treatment Type, 2015 to 2021
Table 20: Latin America Market Value (US$ Mn), By Treatment Type, 2022 to 2032
Table 21: Latin America Market Value (US$ Mn), By Distribution channels Type, 2015 to 2021
Table 22: Latin America Market Value (US$ Mn), By Distribution channels Type, 2022 to 2032
Table 23: Latin America Market, By Country, 2015 to 2021
Table 24: Latin America Market, By Country, 2022 to 2032
Table 25: Europe Market Value (US$ Mn), By Product Type, 2015 to 2021
Table 26: Europe Market Value (US$ Mn), By Product Type, 2022 to 2032
Table 27: Europe Market Value (US$ Mn), By Treatment Type, 2015 to 2021
Table 28: Europe Market Value (US$ Mn), By Treatment Type, 2022 to 2032
Table 29: Europe Market Value (US$ Mn), By Distribution channels Type, 2015 to 2021
Table 30: Europe Market Value (US$ Mn), By Distribution channels Type, 2022 to 2032
Table 31: Europe Market, By Country, 2015 to 2021
Table 32: Europe Market, By Country, 2022 to 2032
Table 33: Asia Pacific Market Value (US$ Mn), By Product Type, 2015 to 2021
Table 34: Asia Pacific Market Value (US$ Mn), By Product Type, 2022 to 2032
Table 35: Asia Pacific Market Value (US$ Mn), By Treatment Type, 2015 to 2021
Table 36: Asia Pacific Market Value (US$ Mn), By Treatment Type, 2022 to 2032
Table 37: Asia Pacific Market Value (US$ Mn), By Distribution channels Type, 2015 to 2021
Table 38: Asia Pacific Market Value (US$ Mn), By Distribution channels Type, 2022 to 2032
Table 39: Asia Pacific Market, By Country, 2015 to 2021
Table 40: Asia Pacific Market, By Country, 2022 to 2032
Table 41: MEA Market Value (US$ Mn), By Product Type, 2015 to 2021
Table 42: MEA Market Value (US$ Mn), By Product Type, 2022 to 2032
Table 43: MEA Market Value (US$ Mn), By Treatment Type, 2015 to 2021
Table 44: MEA Market Value (US$ Mn), By Treatment Type, 2022 to 2032
Table 45: MEA Market Value (US$ Mn), By Distribution channels Type, 2015 to 2021
Table 46: MEA Market Value (US$ Mn), By Distribution channels Type, 2022 to 2032
Table 47: MEA Market, By Country, 2015 to 2021
Table 48: MEA Market, By Country, 2022 to 2032
Table 49: Global Market Incremental $ Opportunity, By Product Type, 2015 to 2021
Table 50: Global Market Incremental $ Opportunity, By Treatment Type, 2022 to 2032
Table 51: Global Market Incremental $ Opportunity, By Distribution channels Type, 2015 to 2021
Table 52: Global Market Incremental $ Opportunity, By Region, 2022 to 2032
Table 53: North America Market Incremental $ Opportunity, By Product Type, 2015 to 2021
Table 54: North America Market Incremental $ Opportunity, By Treatment Type, 2022 to 2032
Table 55: North America Market Incremental $ Opportunity, By Distribution channels Type, 2015 to 2021
Table 56: North America Market Incremental $ Opportunity, By Country, 2022 to 2032
Table 57: Latin America Market Incremental $ Opportunity, By Product Type, 2015 to 2021
Table 58: Latin America Market Incremental $ Opportunity, By Treatment Type, 2022 to 2032
Table 59: Latin America Market Incremental $ Opportunity, By Distribution channels Type, 2015 to 2021
Table 60: Latin America Market Incremental $ Opportunity, By Country, 2022 to 2032
Table 61: Europe Market Incremental $ Opportunity, By Product Type, 2015 to 2021
Table 62: Europe Market Incremental $ Opportunity, By Treatment Type, 2022 to 2032
Table 63: Europe Market Incremental $ Opportunity, By Distribution channels Type, 2015 to 2021
Table 64: Europe Market Incremental $ Opportunity, By Country, 2022 to 2032
Table 65: Asia Pacific Market Incremental $ Opportunity, By Product Type, 2015 to 2021
Table 66: Asia Pacific Market Incremental $ Opportunity, By Treatment Type, 2022 to 2032
Table 67: Asia Pacific Market Incremental $ Opportunity, By Distribution channels Type, 2015 to 2021
Table 68: Asia Pacific Market Incremental $ Opportunity, By Country, 2022 to 2032
Table 69: MEA Market Incremental $ Opportunity, By Product Type, 2015 to 2021
Table 70: MEA Market Incremental $ Opportunity, By Treatment Type, 2022 to 2032
Table 71: MEA Market Incremental $ Opportunity, By Distribution channels Type, 2015 to 2021
Table 72: MEA Market Incremental $ Opportunity, By Country, 2022 to 2032
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Value (US$ Mn) and Year-on-Year Growth, 2015 to 2032
Figure 02: Global Market Absolute $ Historical Gain (2015 to 2021) and Opportunity (2022 to 2032), US$ Mn
Figure 03: Global Market Share, By Product Type, 2022 & 2032
Figure 04: Global Market Y-o-Y Growth Projections, By Product Type – 2022 to 2032
Figure 05: Global Market Attractiveness Index, By Product Type – 2022 to 2032
Figure 06: Global Market Share, By Treatment Type, 2022 & 2032
Figure 07: Global Market Y-o-Y Growth Projections, By Treatment Type – 2022 to 2032
Figure 08: Global Market Attractiveness Index, By Treatment Type – 2022 to 2032
Figure 09: Global Market Share, By Distribution channels Type, 2022 & 2032
Figure 10: Global Market Y-o-Y Growth Projections, By Distribution channels Type – 2022 to 2032
Figure 11: Global Market Attractiveness Index, By Distribution channels Type – 2022 to 2032
Figure 12: Global Market Share, By Region, 2022 & 2032
Figure 13: Global Market Y-o-Y Growth Projections, By Region – 2022 to 2032
Figure 14: Global Market Attractiveness Index, By Region – 2022 to 2032
Figure 15: North America Market Value (US$ Mn) and Year-on-Year Growth, 2015 to 2032
Figure 16: North America Market Absolute $ Opportunity Historical (2015 to 2021) and Forecast Period (2022–2032), US$ Mn
Figure 17: North America Market Share, By Product Type, 2022 & 2032
Figure 18: North America Market Y-o-Y Growth Projections, By Product Type – 2022 to 2032
Figure 19: North America Market Attractiveness Index, By Product Type – 2022 to 2032
Figure 20: North America Market Share, By Treatment Type, 2022 & 2032
Figure 21: North America Market Y-o-Y Growth Projections, By Treatment Type – 2022 to 2032
Figure 22: North America Market Attractiveness Index, By Treatment Type – 2022 to 2032
Figure 23: North America Market Share, By Distribution channels Type, 2022 & 2032
Figure 24: North America Market Y-o-Y Growth Projections, By Distribution channels Type – 2022 to 2032
Figure 25: North America Market Attractiveness Index, By Distribution channels Type – 2022 to 2032
Figure 26: North America Market Share, By Country, 2022 & 2032
Figure 27: North America Market Y-o-Y Growth Projections, By Country – 2022 to 2032
Figure 28: North America Market Attractiveness Index, By Country – 2022 to 2032
Figure 29: Latin America Market Value (US$ Mn) and Year-on-Year Growth, 2015 to 2032
Figure 30: Latin America Market Absolute $ Opportunity Historical (2015 to 2021) and Forecast Period (2022–2032), US$ Mn
Figure 31: Latin America Market Share, By Product Type, 2022 & 2032
Figure 32: Latin America Market Y-o-Y Growth Projections, By Product Type – 2022 to 2032
Figure 33: Latin America Market Attractiveness Index, By Product Type – 2022 to 2032
Figure 34: Latin America Market Share, By Treatment Type, 2022 & 2032
Figure 35: Latin America Market Y-o-Y Growth Projections, By Treatment Type – 2022 to 2032
Figure 36: Latin America Market Attractiveness Index, By Treatment Type – 2022 to 2032
Figure 37: Latin America Market Share, By Distribution channels Type, 2022 & 2032
Figure 38: Latin America Market Y-o-Y Growth Projections, By Distribution channels Type – 2022 to 2032
Figure 39: Latin America Market Attractiveness Index, By Distribution channels Type – 2022 to 2032
Figure 40: Latin America Market Share, By Country, 2022 & 2032
Figure 41: Latin America Market Y-o-Y Growth Projections, By Country – 2022 to 2032
Figure 42: Latin America Market Attractiveness Index, By Country – 2022 to 2032
Figure 43: Europe Market Value (US$ Mn) and Year-on-Year Growth, 2015 to 2032
Figure 44: Europe Market Absolute $ Opportunity Historical (2015 to 2021) and Forecast Period (2022 to 2032), US$ Mn
Figure 45: Europe Market Share, By Product Type, 2022 & 2032
Figure 46: Europe Market Y-o-Y Growth Projections, By Product Type – 2022 to 2032
Figure 47: Europe Market Attractiveness Index, By Product Type – 2022 to 2032
Figure 48: Europe Market Share, By Treatment Type, 2022 & 2032
Figure 49: Europe Market Y-o-Y Growth Projections, By Treatment Type – 2022 to 2032
Figure 50: Europe Market Attractiveness Index, By Treatment Type – 2022 to 2032
Figure 51: Europe Market Share, By Distribution channels Type, 2022 & 2032
Figure 52: Europe Market Y-o-Y Growth Projections, By Distribution channels Type – 2022 to 2032
Figure 53: Europe Market Attractiveness Index, By Distribution channels Type – 2022 to 2032
Figure 54: Europe Market Share, By Country, 2022 & 2032
Figure 55: Europe Market Y-o-Y Growth Projections, By Country – 2022 to 2032
Figure 56: Europe Market Attractiveness Index, By Country – 2022 to 2032
Figure 57: MEA Market Value (US$ Mn) and Year-on-Year Growth, 2015 to 2032
Figure 58: MEA Market Absolute $ Opportunity Historical (2015 to 2021) and Forecast Period (2022 to 2032), US$ Mn
Figure 59: MEA Market Share, By Product Type, 2022 & 2032
Figure 60: MEA Market Y-o-Y Growth Projections, By Product Type – 2022 to 2032
Figure 61: MEA Market Attractiveness Index, By Product Type – 2022 to 2032
Figure 62: MEA Market Share, By Treatment Type, 2022 & 2032
Figure 63: MEA Market Y-o-Y Growth Projections, By Treatment Type – 2022 to 2032
Figure 64: MEA Market Attractiveness Index, By Treatment Type – 2022 to 2032
Figure 65: MEA Market Share, By Distribution channels Type, 2022 & 2032
Figure 66: MEA Market Y-o-Y Growth Projections, By Distribution channels Type – 2022 to 2032
Figure 67: MEA Market Attractiveness Index, By Distribution channels Type – 2022 to 2032
Figure 68: MEA Market Share, By Country, 2022 & 2032
Figure 69: MEA Market Y-o-Y Growth Projections, By Country – 2022 to 2032
Figure 70: MEA Market Attractiveness Index, By Country – 2022 to 2032
Figure 71: Asia Pacific Market Value (US$ Mn) and Year-on-Year Growth, 2015 to 2032
Figure 72: Asia Pacific Market Absolute $ Opportunity Historical (2015 to 2021) and Forecast Period (2022 to 2032),US$ Mn
Figure 73: Asia Pacific Market Share, By Product Type, 2022 & 2032
Figure 74: Asia Pacific Market Y-o-Y Growth Projections, By Product Type – 2022 to 2032
Figure 75: Asia Pacific Market Attractiveness Index, By Product Type – 2022 to 2032
Figure 76: Asia Pacific Market Share, By Treatment Type, 2022 & 2032
Figure 77: Asia Pacific Market Y-o-Y Growth Projections, By Treatment Type – 2022 to 2032
Figure 78: Asia Pacific Market Attractiveness Index, By Treatment Type – 2022 to 2032
Figure 79: Asia Pacific Market Share, By Distribution channels Type, 2022 & 2032
Figure 80: Asia Pacific Market Y-o-Y Growth Projections, By Distribution channels Type – 2022 to 2032
Figure 81: Asia Pacific Market Attractiveness Index, By Distribution channels Type – 2022 to 2032
Figure 82: Asia Pacific Market Share, By Country, 2022 & 2032
Figure 83: Asia Pacific Market Y-o-Y Growth Projections, By Country – 2022 to 2032
Figure 84: Asia Pacific Market Attractiveness Index, By Country – 2022 to 2032
Figure 85: US Market Value (US$ Mn) and Forecast, 2022 to 2032
Figure 86: US Market Share, By Product Type, 2021
Figure 87: US Market Share, By Treatment Type, 2021
Figure 88: US Market Share, By Distribution channels Type, 2021
Figure 89: Canada Market Value (US$ Mn) and Forecast, 2022 to 2032
Figure 90: Canada Market Share, By Product Type, 2021
Figure 91: Canada Market Share, By Treatment Type, 2021
Figure 92: Canada Market Share, By Distribution channels Type, 2021
Figure 93: Brazil Market Value (US$ Mn) and Forecast, 2022 to 2032
Figure 94: Brazil Market Share, By Product Type, 2021
Figure 95: Brazil Market Share, By Treatment Type, 2021
Figure 96: Brazil Market Share, By Distribution channels Type, 2021
Figure 97: Mexico Market Value (US$ Mn) and Forecast, 2022 to 2032
Figure 98: Mexico Market Share, By Product Type, 2021
Figure 99: Mexico Market Share, By Treatment Type, 2021
Figure 100: Mexico Market Share, By Distribution channels Type, 2021
Figure 101: Germany Market Value (US$ Mn) and Forecast, 2022 to 2032
Figure 102: Germany Market Share, By Product Type, 2021
Figure 103: Germany Market Share, By Treatment Type, 2021
Figure 104: Germany Market Share, By Distribution channels Type, 2021
Figure 105: U.K. Market Value (US$ Mn) and Forecast, 2022 to 2032
Figure 106: U.K. Market Share, By Product Type, 2021
Figure 107: U.K. Market Share, By Treatment Type, 2021
Figure 108: U.K. Market Share, By Distribution channels Type, 2021
Figure 109: France Market Value (US$ Mn) and Forecast, 2022 to 2032
Figure 110: France Market Share, By Product Type, 2021
Figure 111: France Market Share, By Treatment Type, 2021
Figure 112: France Market Share, By Distribution channels Type, 2021
Figure 113: Italy Market Value (US$ Mn) and Forecast, 2022 to 2032
Figure 114: Italy Market Share, By Product Type, 2021
Figure 115: Italy Market Share, By Treatment Type, 2021
Figure 116: Italy Market Share, By Distribution channels Type, 2021
Figure 117: BENELUX Market Value (US$ Mn) and Forecast, 2022 to 2032
Figure 118: BENELUX Market Share, By Product Type, 2021
Figure 119: BENELUX Market Share, By Treatment Type, 2021
Figure 120: BENELUX Market Share, By Distribution channels Type, 2021
Figure 121: Nordic Countries Market Value (US$ Mn) and Forecast, 2022 to 2032
Figure 122: Nordic Countries Market Share, By Product Type, 2021
Figure 123: Nordic Countries Market Share, By Treatment Type, 2021
Figure 124: Nordic Countries Market Share, By Distribution channels Type, 2021
Figure 125: China Market Value (US$ Mn) and Forecast, 2022 to 2032
Figure 126: China Market Share, By Product Type, 2021
Figure 127: China Market Share, By Treatment Type, 2021
Figure 128: China Market Share, By Distribution channels Type, 2021
Figure 129: Japan Market Value (US$ Mn) and Forecast, 2022 to 2032
Figure 130: Japan Market Share, By Product Type, 2021
Figure 131: Japan Market Share, By Treatment Type, 2021
Figure 132: Japan Market Share, By Distribution channels Type, 2021
Figure 133: South Korea Market Value (US$ Mn) and Forecast, 2022 to 2032
Figure 134: South Korea Market Share, By Product Type, 2021
Figure 135: South Korea Market Share, By Treatment Type, 2021
Figure 136: South Korea Market Share, By Distribution channels Type, 2021
Figure 137: GCC Countries Market Value (US$ Mn) and Forecast, 2022 to 2032
Figure 138: GCC Countries Market Share, By Product Type, 2021
Figure 139: GCC Countries Market Share, By Treatment Type, 2021
Figure 140: GCC Countries Market Share, By Distribution channels Type, 2021
Figure 141: South Africa Market Value (US$ Mn) and Forecast, 2022 to 2032
Figure 142: South Africa Market Share, By Product Type, 2021
Figure 143: South Africa Market Share, By Treatment Type, 2021
Figure 144: South Africa Market Share, By Distribution channels Type, 2021
Figure 145: Turkey Market Value (US$ Mn) and Forecast, 2022 to 2032
Figure 146: Turkey Market Share, By Product Type, 2021
Figure 147: Turkey Market Share, By Treatment Type, 2021
Figure 148: Turkey Market Share, By Distribution channels Type, 2021
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What was the market worth for idiopathic thrombocytopenic purpura therapeutics in 2021?
As of 2021, the idiopathic thrombocytopenic purpura therapeutics market was estimated to have reached US$ 587.0 Million
What is the expected worth of the idiopathic thrombocytopenic purpura therapeutics industry in 2022?
By 2022, the market for idiopathic thrombocytopenic purpura therapeutics is expected to reach US$ 620.5 Million
At what CAGR did the idiopathic thrombocytopenic purpura therapeutics market flourish from 2015-2021?
From 2015-2021, the idiopathic thrombocytopenic purpura therapeutics market grew at a 5.6% value CAGR
What is the expected forecast CAGR for idiopathic thrombocytopenic purpura therapeutics from 2022-2032?
From 2022-2032, idiopathic thrombocytopenic purpura therapeutics demand is likely to surge at a 5.0% CAGR
At what value will the market for idiopathic thrombocytopenic purpura therapeutics close in 2032?
By 2032, the market for idiopathic thrombocytopenic purpura therapeutics is likely to be valued at US$ 1.0 Billion
What is the expected market value for the U.S idiopathic thrombocytopenic purpura therapeutics market?
By 2032, Fact.MR expects the U.S market for idiopathic thrombocytopenic purpura therapeutics to reach US$ 361.8 Million
How opportunistic is the Chinese market for idiopathic thrombocytopenic purpura therapeutics?
China is expected to register a 4.4% CAGR with regard to the Idiopathic Thrombocytopenic Purpura Therapeutics Industry
What is the expected growth rate for the Japanese market?
Japan is expected to document a CAGR worth 3.4% in the idiopathic thrombocytopenic purpura therapeutics market
Which product type will account for the maximum idiopathic thrombocytopenic purpura therapeutics revenue?
By product type, corticosteroids will expand the fastest, expanding at a 5.0% CAGR
By distribution channel, which category is likely to remain prominent until 2032?
By distribution channel, retail pharmacies will remain most prominent category, expanding at CAGR of 5.1% until 2032
Idiopathic Thrombocytopenic Purpura Therapeutics Market